XUI

2-{6-[4-(cyclopentanecarbonyl)piperazin-1-yl]-4-oxoquinazolin-3(4H)-yl}-N-[(3,4-dichlorophenyl)methyl]acetamide

Created:	2023-06-08
Last modified:	2024-12-18

Find Related PDB Entry
1 entries where XUI is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	66
Chiral Atom Count	0
Bond Count	70
Aromatic Bond Count	12

2D diagram of XUI

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	2-{6-[4-(cyclopentanecarbonyl)piperazin-1-yl]-4-oxoquinazolin-3(4H)-yl}-N-[(3,4-dichlorophenyl)methyl]acetamide
Systematic Name (OpenEye OEToolkits)	2-[6-(4-cyclopentylcarbonylpiperazin-1-yl)-4-oxidanylidene-quinazolin-3-yl]-~{N}-[(3,4-dichlorophenyl)methyl]ethanamide
Formula	C₂₇ H₂₉ Cl₂ N₅ O₃
Molecular Weight	542.457
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	O=C(C1CCCC1)N1CCN(CC1)c1cc2C(=O)N(CC(=O)NCc3ccc(Cl)c(Cl)c3)C=Nc2cc1
SMILES	CACTVS	3.385	Clc1ccc(CNC(=O)CN2C=Nc3ccc(cc3C2=O)N4CCN(CC4)C(=O)C5CCCC5)cc1Cl
SMILES	OpenEye OEToolkits	2.0.7	c1cc(c(cc1CNC(=O)CN2C=Nc3ccc(cc3C2=O)N4CCN(CC4)C(=O)C5CCCC5)Cl)Cl
Canonical SMILES	CACTVS	3.385	Clc1ccc(CNC(=O)CN2C=Nc3ccc(cc3C2=O)N4CCN(CC4)C(=O)C5CCCC5)cc1Cl
Canonical SMILES	OpenEye OEToolkits	2.0.7	c1cc(c(cc1CNC(=O)CN2C=Nc3ccc(cc3C2=O)N4CCN(CC4)C(=O)C5CCCC5)Cl)Cl
InChI	InChI	1.06	InChI=1S/C27H29Cl2N5O3/c28-22-7-5-18(13-23(22)29)15-30-25(35)16-34-17-31-24-8-6-20(14-21(24)27(34)37)32-9-11-33(12-10-32)26(36)19-3-1-2-4-19/h5-8,13-14,17,19H,1-4,9-12,15-16H2,(H,30,35)
InChIKey	InChI	1.06	GQWGTQUITMTEIN-UHFFFAOYSA-N

Related Resource References

Resource Name	Reference
PubChem	122603721

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.